Ribociclib Succinate Crystallization via Lithium Catalyst
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing method for preparing ribociclib succinate requires a costly noble-metal catalyst, palladium acetate, and results in crystalline polymorphism that compromises storage stability and efficacy.
Innovation Solution
The method uses lithium bis(trimethylsilyl)amine instead of palladium acetate and employs low-toxicity solvents like ethanol or isopropanol to produce ribociclib succinates in crystalline forms B, C, and D, which are stable and suitable for industrial production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If palladium acetate is used as a catalyst in the preparation method, then the reaction can proceed effectively, but the production cost increases significantly
Solution Approach 1:
The patent replaces the expensive noble metal catalyst (palladium acetate) with a cheap organic catalyst (lithium bis(trimethylsilyl)amine). This organic catalyst achieves the same catalytic function of facilitating the coupling reaction between ribociclib and succinic acid, but at a fraction of the cost, making the preparation method economically viable for industrial production
Solution Approach 2:
The patent changes the fundamental parameter of catalyst type from noble metal-based to organic-based. This parameter change fundamentally alters the cost structure of the reaction while maintaining catalytic effectiveness, enabling cost-effective large-scale production of ribociclib succinate
2Productivity
If conventional preparation methods are used, then ribociclib succinate can be produced, but crystalline polymorphism occurs which compromises storage stability
Solution Approach 1:
The patent changes the reaction parameters including catalyst type, solvent system (using ethanol or isopropanol), temperature profile, and addition rate to control the crystallization process. These parameter changes ensure that ribociclib succinate crystallizes in a single stable polymorphic form rather than exhibiting polymorphism, thereby guaranteeing storage stability while maintaining production capability
Solution Approach 2:
The patent employs preliminary action by carefully controlling the reaction conditions and crystallization parameters before the actual product formation. By pre-establishing optimal temperature, solvent, and addition rate conditions, the method ensures that the desired stable crystalline form is obtained from the outset, preventing polymorphic complications during storage
3Ease of manufacture
If excessive organic solvents are used in conventional synthetic methods, then the reaction can proceed, but health hazards and toxic solvent residues increase
Solution Approach 1:
The patent changes the solvent parameter by selecting ethanol or isopropanol as the reaction medium instead of excessive or highly toxic organic solvents. These alternative solvents are effective for dissolving reactants and facilitating the reaction but are much less toxic and can be more easily removed, reducing health hazards and residual contamination in the final pharmaceutical product
Solution Approach 2:
The patent uses readily available, low-toxicity solvents (ethanol or isopropanol) that can be easily evaporated or removed. These solvents serve their purpose during the reaction and can be completely eliminated from the final product, leaving no harmful residues, whereas conventional solvents may leave persistent toxic traces
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces production costs, minimizes toxic solvent residues, and ensures storage stability of ribociclib succinates, making them suitable for therapeutic pharmaceutical compositions.
Implementation Method 1
the method uses lithium bis(trimethylsilyl)amine instead of palladium acetate
Implementation Method 2
cooling the mixed solution, and then filtering the mixed solution to obtain a ribociclib succinate in crystalline form B, C, or D
Data Source
AI summary
The present invention relates to crystal forms B, C and D of Ribociclib succinate salt and derivatives thereof, and their preparation method and composition. The crystal forms B, C and D of Ribociclib succinate salts are obtained by adding 7-cyclopentyl-N,N-dimethyl-2-(5-(piperain-1-yl)pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide solution into succinic acid solution for reaction, stirring the solution under high temperature, filtering the solution after cooling off.